Showing 4941-4950 of 6036 results for "".
- AffaMed Therapeutics and SIFI Announce Joint Venture to Serve Greater China Markethttps://modernod.com/news/affamed-therapeutics-and-sifi-announce-joint-venture-to-serve-greater-china-market/2479036/AffaMed Therapeutics and SIFI S.p.A. announced they have entered into an agreement to establish a joint venture to develop, manufacture and commercialize premium IOLs in the Greater China market, including Mainland China, Taiwan, Macau and Hong Kong. AffaMed will provide funding for growth
- Surface Ophthalmics Announces Preeya K. Gupta, MD, as Chief Medical Advisorhttps://modernod.com/news/surface-ophthalmics-announces-preeya-k-gupta-md-as-chief-medical-advisor/2479032/Surface Ophthalmics announced the appointment of Preeya K. Gupta, MD, as Chief Medical Advisor (CMA). Dr. Gupta will consult with Surface Ophthalmics leaders and lend her expertise, particularly in dry eye disease, to help guide Surface’s three clinical progra
- FDA Approves Rayner’s RayOne EMV IOLhttps://modernod.com/news/fda-approves-rayners-rayone-emv-iol/2479019/Rayner’s RayOne EMV fully preloaded non-diffractive IOL has received FDA approval. RayOne EMV was developed in collaboration with renowned surgeon Professor Graham Barrett, president of the Australasian Society of Cataract & Refractive Surgeons. Dr. Mariano Royo, Director
- Gyroscope Therapeutics Announces $148 Million Raised in Series C Financinghttps://modernod.com/news/gyroscope-therapeutics-announces-148-million-raised-in-series-c-financing/2479018/Gyroscope Therapeutics announced it has raised $148.0 million (£107.8 million) in a Series C financing. Gyroscope plans to use proceeds from the financing to advance the clinical development of GT005,
- Intel AI-Powered Backpack Helps Visually Impaired Navigate Worldhttps://modernod.com/news/intel-ai-powered-backpack-helps-visually-impaired-navigate-world/2479014/Artificial intelligence (AI) developer Jagadish K. Mahendran and his team designed an AI-powered, voice-activated backpack that can help the visually impaired navigate and perceive the world around them. The backpack helps detect common challenges such as traffic signs, hanging obstacles, crosswa
- Lineage Cell Therapeutics Presents Additional Interim Data on OpRegen for Dry AMD With Geographic Atrophyhttps://modernod.com/news/lineage-cell-therapeutics-presents-additional-interim-data-on-opregen-for-dry-amd-with-geographic-atrophy/2479007/Lineage Cell Therapeutics announced new positive interim results from its ongoing, 24-patient phase 1/2a clinical study of its lead product candidate, OpRegen. OpRegen is an investigational cell therapy consisting of allogeneic retinal pigment epithelium (RPE) cells administered to the subretinal
- ProQR Announces Positive Results From Clinical Trial of QR-421a in Usher Syndrome and Plans to Start Pivotal Trialshttps://modernod.com/news/proqr-announces-positive-results-from-clinical-trial-of-qr-421a-in-usher-syndrome-and-plans-to-start-pivotal-trials/2479006/ProQR Therapeutics announced results from a planned analysis of its phase 1/2 Stellar trial of QR-421a in adults with Usher syndrome and non-syndromic retinitis pigmentosa (nsRP) due to USH2A exon 13 mutations. In the trial, QR-421a demonstrated benefit on multiple measures of v
- AdHawk Microsystems Launches AdHawk MindLink Eye Tracking Researchhttps://modernod.com/news/adhawk-microsystems-launches-adhawk-mindlink-eye-tracking-research/2479002/AdHawk Microsystems announced the launch of AdHawk MindLink wearable eye tracking system. AdHawk MindLink produces accurate eye movement data to provide deep insights into human behavior, ocular, and neurological health. Delivered in the form of lightweight and comfortable glasses, the AdHawk sys
- New Open Access Ophthalmology Journal Now Livehttps://modernod.com/news/new-open-access-ophthalmology-journal-now-live/2478998/Ophthalmology Science—the American Academy of Ophthalmology’s first open access journal—is now live and accepting submissions. Ophthalmology Science is an online open access journal focused on publishing preclinical development, phase 1 and 2 clinical trials, laboratory
- SemaThera Enters into a Research Collaboration and Exclusive License Agreement with Rochehttps://modernod.com/news/semathera-enters-into-a-research-collaboration-and-exclusive-license-agreement-with-roche/2478997/SemaThera announced the signing of a multi-year research collaboration and licensing agreement with Roche to advance SemaThera’s new class of biologicals for the treatment of diabetic retinopathy and other ischemic retinal diseases. Terms of the deal were not disclosed. “We are very